[{"address1": "7 Times Square", "address2": "Suite 2503", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 48, "title": "Founder, President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 994385, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Thomas Burns CPA", "age": 39, "title": "Senior VP & CFO", "yearBorn": 1985, "fiscalYear": 2024, "totalPay": 620894, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dragan  Cicic M.D., MBA", "age": 61, "title": "Senior VP & Chief Development Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 659364, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy E. Yeung", "title": "VP of Legal Affairs, Head of Compliance & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Elnatan", "title": "Senior VP of Regulatory Affairs, CMC & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.57, "open": 1.53, "dayLow": 1.5, "dayHigh": 1.57, "regularMarketPreviousClose": 1.57, "regularMarketOpen": 1.53, "regularMarketDayLow": 1.5, "regularMarketDayHigh": 1.57, "payoutRatio": 0.0, "beta": 2.274, "forwardPE": -3.5813951, "volume": 3074044, "regularMarketVolume": 3074044, "averageVolume": 2161712, "averageVolume10days": 2383160, "averageDailyVolume10Day": 2383160, "bid": 1.11, "ask": 1.95, "bidSize": 2, "askSize": 2, "marketCap": 153657360, "fiftyTwoWeekLow": 0.77, "fiftyTwoWeekHigh": 2.12, "fiftyDayAverage": 1.5452, "twoHundredDayAverage": 1.26465, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 126130328, "profitMargins": 0.0, "floatShares": 91877106, "sharesOutstanding": 99777504, "sharesShort": 12221572, "sharesShortPriorMonth": 7709569, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.1225, "heldPercentInsiders": 0.0033500001, "heldPercentInstitutions": 0.14336, "shortRatio": 4.15, "shortPercentOfFloat": 0.1238, "impliedSharesOutstanding": 99777504, "bookValue": 0.305, "priceToBook": 5.04918, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -27128000, "trailingEps": -0.36, "forwardEps": -0.43, "lastSplitFactor": "1:50", "lastSplitDate": 1573171200, "52WeekChange": 0.27272725, "SandP52WeekChange": 0.09544468, "quoteType": "EQUITY", "currentPrice": 1.54, "targetHighPrice": 7.5, "targetLowPrice": 4.0, "targetMeanPrice": 5.83333, "targetMedianPrice": 6.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 28397000, "totalCashPerShare": 0.285, "totalDebt": 870000, "quickRatio": 4.123, "currentRatio": 4.642, "debtToEquity": 3.134, "returnOnAssets": -0.58787, "returnOnEquity": -1.44903, "freeCashflow": -23975876, "operatingCashflow": -33711000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "SLS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "SELLAS Life Sciences Group, Inc", "longName": "SELLAS Life Sciences Group, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1205328600000, "postMarketChangePercent": 0.64935005, "postMarketPrice": 1.55, "postMarketChange": 0.00999999, "regularMarketChange": -0.0300001, "regularMarketDayRange": "1.5 - 1.57", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2161712, "fiftyTwoWeekLowChange": 0.77, "fiftyTwoWeekLowChangePercent": 1.0, "fiftyTwoWeekRange": "0.77 - 2.12", "fiftyTwoWeekHighChange": -0.5799999, "fiftyTwoWeekHighChangePercent": -0.27358487, "fiftyTwoWeekChangePercent": 27.272724, "dividendDate": 1573171200, "earningsTimestamp": 1747166701, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.36, "epsForward": -0.43, "epsCurrentYear": -0.31667, "priceEpsCurrentYear": -4.8631067, "corporateActions": [], "postMarketTime": 1750463564, "regularMarketTime": 1750449601, "exchange": "NCM", "messageBoardId": "finmb_262231850", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.91083, "regularMarketPrice": 1.54, "fiftyDayAverageChange": -0.0052000284, "fiftyDayAverageChangePercent": -0.0033652785, "twoHundredDayAverageChange": 0.27534997, "twoHundredDayAverageChangePercent": 0.21772821, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "SELLAS Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-06-21"}]